Citations

Clear

11 citation(s) found for "Hacke, Katrin".

Identification of the Novel HLA‐DRB1*03:234 Allele by Next‐Generation Sequencing
Siegel, Ruby J , Hacke, Katrin , Gebhart, Catherine L , Franz, Brian J , Jaramillo, Andres

Mayo Clinic

HLA | October 29, 2026 | Volume: 108 | Issue: 5 | Pages: No page available

10.1111/tan.71063 | PMID 42956409 Get It

ABSTRACT HLA‐DRB1*03:234 differs from HLA‐DRB1*03:01:01:01 by two adjacent nucleotide substitutions in exon 2.
Identification of the Novel HLA‐C*07:1268 Allele by Next‐Generation Sequencing
Siegel, Ruby J. , Hacke, Katrin , Gebhart, Catherine, Franz, Brian J. , Jaramillo, Andrés , Gebhart, Catherine L , Jaramillo, Andres , Hacke, Katrin

Mayo Clinic

HLA | August 4, 2026 | Volume: 108 | Issue: 2 | Pages: No page available

10.1111/tan.70895 | PMID 42550108 Get It

ABSTRACT HLA‐C*07:1268 differs from HLA‐C*07:02:01:01 by one nucleotide substitution in exon 3.
Identification of the Novel HLA‐B*08:345Q Allele by Next‐Generation Sequencing
Siegel, Ruby J. , Hacke, Katrin , Gebhart, Catherine, Ridgley, Rose M., Jaramillo, Andrés , Gebhart, Catherine L, Jaramillo, Andres , Hacke, Katrin , Gebhart, Catherine L

Mayo Clinic

HLA | May 21, 2026 | Volume: 107 | Issue: 5 | Pages: No page available

10.1111/tan.70763 | PMID 42165123 Get It

ABSTRACT HLA‐B*08:345Q differs from HLA‐B*08:238 by one nucleotide substitution, introducing a premature stop codon in exon 5.
Identification of the Novel HLA ‐A*32:202 Allele by Next‐Generation Sequencing and Oxford Nanopore Sequencing
Siegel, Ruby J. , Ho, S., Hacke, Katrin, Ridgley, Rose M., Jaramillo, Andrés, Ho, Chak‐Sum , Jaramillo, Andrés , Hacke, Katrin , Ho, Sam , Hacke, Katrin , Jaramillo, Andres , Ho, Sam

Mayo Clinic

HLA | March 25, 2026 | Volume: 107 | Issue: 4 | Pages: No page available

10.1111/tan.70687 | PMID 41877497 Get It

ABSTRACT HLA‐A*32:202 differs from HLA‐A*32:01:01:01 by two nucleotide substitutions in exons 1 and 2.
Identification of the HLA‐DQB1*06:144N Allele by Next‐Generation Sequencing
Siegel, Ruby J. , Hacke, Katrin, Ridgley, Rose M., Troop, Danielle M., Jaramillo, Andrés, Jaramillo, Andrés , Hacke, Katrin , Hacke, Katrin , Jaramillo, Andres

Mayo Clinic

HLA | March 8, 2026 | Volume: 107 | Issue: 2 | Pages: No page available

10.1111/tan.70628 | PMID 41732979 Get It

ABSTRACT HLA‐DQB1*06:144N differs from HLA‐DQB1*06:03:01:01 by one nucleotide substitution, introducing a premature stop codon in exon 2.
Identification of the Novel HLA‐B*57:205 Allele by Next‐Generation Sequencing
Siegel, Ruby J. , Hacke, Katrin, Ridgley, Rose M., Troop, Danielle M., Jaramillo, Andrés, Jaramillo, Andrés , Hacke, Katrin , Hacke, Katrin , Jaramillo, Andres

Mayo Clinic

HLA | March 8, 2026 | Volume: 107 | Issue: 2 | Pages: No page available

10.1111/tan.70622 | PMID 41757488 Get It

ABSTRACT HLA‐B*57:205 differs from HLA‐B*57:01:01:01 by one nucleotide substitution in Exon 1.
Identification of the Novel HLA‐A*24:675 Allele by Next‐Generation Sequencing
Siegel, Ruby J. , Hacke, Katrin, Ridgley, Rose M., Troop, Danielle M., Jaramillo, Andrés, Jaramillo, Andrés , Hacke, Katrin , Hacke, Katrin , Jaramillo, Andres

Mayo Clinic

HLA | March 8, 2026 | Volume: 107 | Issue: 2 | Pages: No page available

10.1111/tan.70621 | PMID 41732822 Get It

ABSTRACT HLA‐A*24:675 differs from HLA‐A*24:02:01:01 by one nucleotide substitution in exon 3.
Identification of the Novel HLA‐DQB1*06:549 Allele by Next‐Generation Sequencing
Siegel, Ruby J. , Hacke, Katrin, Ridgley, Rose M., Troop, Danielle M., Jaramillo, Andrés, Jaramillo, Andrés , Hacke, Katrin , Hacke, Katrin , Jaramillo, Andres

Mayo Clinic

HLA | February 23, 2026 | Volume: 107 | Issue: 2 | Pages: No page available

10.1111/tan.70612 | PMID 41757479 Get It

ABSTRACT HLA‐DQB1*06:549 differs from HLA‐DQB1*06:02:01:01 by one nucleotide substitution in exon 2.
Identification of the Novel HLA‐C*03:737 Allele by Next‐Generation Sequencing
Siegel, Ruby J. , Hacke, Katrin, Ridgley, Rose M., Troop, Danielle M., Jaramillo, Andrés, Jaramillo, Andrés , Hacke, Katrin , Hacke, Katrin , Jaramillo, Andres

Mayo Clinic

HLA | February 20, 2026 | Volume: 107 | Issue: 2 | Pages: No page available

10.1111/tan.70615 | PMID 41717859 Get It

ABSTRACT HLA‐C*03:737 differs from HLA‐C*03:05:01:01 by one nucleotide substitution in exon 3.
Subclinical Pancreas Rejection on Protocol Biopsy Within the First Year of Simultaneous Pancreas Kidney Transplant
Budhiraja, Pooja , Heilman, Raymond L. , Butterfield, Richard , Reddy, Kunam S. , Khamash, Hassan A., Jawdeh, Bassam G. Abu , Katariya, Nitin , Smith, Maxwell L. , Jaramillo, Andrés , Alajous, Salah, Mathur, Amit K. , Hacke, Katrin , Khamash, Hassan , Abu Jawdeh, Bassam G , Jadlowiec, Caroline , Katariya, Nitin N , Smith, Maxwell , Jaramillo, Andres , Mathur, Amit , Hacke, Katrin , Chakkera, Harini A , Butterfield, Richard J , Budhiraja, Pooja , Jadlowiec, Caroline C. , Chakkera, Harini A.

Mayo Clinic

Clinical Transplantation | September 26, 2024 | Volume: 38 | Issue: 10 | Pages: No page available

10.1111/ctr.15467 | PMID 39324885 Get It

ABSTRACTThis single‐center retrospective study investigated subclinical rejection prevalence and significance in simultaneous pancreas and kidney transplant (SPKT) recipients. We analyzed 352 SPKT recipients from July 2003 to April 2022. Our protocol included pancreas allograft surveillance biopsies at 1, 4, and 12months post‐transplant. After excluding 153 patients unable to undergo pancreas biopsy, our study cohort comprised 199 recipients. Among the 199 patients with protocol pancreas biopsies, 107 had multiple protocol pancreas biopsies in the first year, totaling 323. Subclinical rejection was identified in 132 episodes (41%). Of these, 72% were Grade 1, 20% were indeterminate, and 8% were Banff Grade 2 or higher. All episodes of subclinical rejection were treated. Rates of pancreas graft loss (10% vs. 7%) and clinical rejection (21% vs. 20%) at 3 years were similar between those with and without subclinical rejection. Subclinical rejection Banff Grade 2 or more was associated with poor pancreas graft survival HR of 5.5 (95% CI: 1.24–24.37, p = 0.025). Of 236 simultaneous protocol kidney and pancreas biopsies, 102 (43%) showed pancreas subclinical rejection, while only 17% had concurrent kidney subclinical rejection. Our findings suggest limited predictive value of pancreatic enzymes and euglycemia in detecting pancreas rejection. Furthermore, poor concordance existed between pancreas and kidney subclinical rejection.